CONSOLIDATED GEMS, INC. (CGEM)

Sorry, no known transcripts

Recent filings

Securities to be offered to employees in employee benefit plans - March 9, 2023

Securities to be offered to employees in employee benefit plans - March 9, 2023

Registration statement under Securities Act of 1933 - March 9, 2023

CONSOLIDATED GEMS, INC. Just Filed Its Annual Report: Earnings (Net Loss) ... - March 9, 2023

CONSOLIDATED GEMS: Cullinan Oncology Provides Corporate Update And - March 9, 2023

CONSOLIDATED GEMS, INC.'s President and CEO just picked up 109,000 shares - Feb. 23, 2023

CONSOLIDATED GEMS, INC.'s Chief Medical Officer just picked up 60,000 shares - Feb. 21, 2023

CONSOLIDATED GEMS, INC.'s Chief Development Officer just picked up 38,500 shares - Feb. 21, 2023

CONSOLIDATED GEMS, INC.'s Chief Financial Officer just picked up 47,000 shares - Feb. 21, 2023

CONSOLIDATED GEMS, INC.'s Chief Business Officer just picked up 20,500 shares - Feb. 21, 2023

CONSOLIDATED GEMS, INC.'s Chief Legal Officer just picked up 47,000 shares - Feb. 21, 2023

CONSOLIDATED GEMS, INC.'s Chief Scientific Officer just picked up 38,500 shares - Feb. 21, 2023

Morana just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 15, 2023

CHI Advisors LLC just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 13, 2023

Major owner of CONSOLIDATED GEMS, INC. just picked up 350,938 shares - Feb. 10, 2023

The Vanguard Group just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 9, 2023

BlackRock, Inc. just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 3, 2023

Major owner of CONSOLIDATED GEMS, INC. just disposed of 6,400,000 shares - Jan. 19, 2023

CONSOLIDATED GEMS, INC.'s Chief Financial Officer just picked up 201 shares - Jan. 6, 2023

CONSOLIDATED GEMS, INC.'s See Remarks just cashed-in 4,000 options - Nov. 29, 2022

CONSOLIDATED GEMS: Cullinan Oncology Provides Corporate Update And - Nov. 14, 2022

CONSOLIDATED GEMS, INC. Just Filed Its Quarterly Report: (13)Earnings per Sha... - Nov. 14, 2022

CONSOLIDATED GEMS, INC. director was just granted 26,150 options - Nov. 2, 2022

CONSOLIDATED GEMS, INC. director just declared ownership of no shares of CONSOLIDATED GEMS, INC. - Nov. 2, 2022

     Departure of Directors or Certain - Nov. 2, 2022

CONSOLIDATED GEMS: Cullinan Oncology Significantly Increases Ownership Stake In Its Mica Subsidiary Which Holds Worldwide Rights To Clinical-Stage Novel Monoclonal Antibody CLN-619 - Oct. 25, 2022

CONSOLIDATED GEMS, INC.'s See Remarks just cashed-in 4,000 options - Sept. 29, 2022

CONSOLIDATED GEMS, INC.'s Chief Legal Officer just declared ownership of no shares of CONSOLIDATED GEMS, INC. - Aug. 16, 2022

CONSOLIDATED GEMS, INC.'s Chief Legal Officer was just granted 190,000 options - Aug. 16, 2022

Major owner of CONSOLIDATED GEMS, INC. just disposed of 49,910 shares - Aug. 4, 2022

CONSOLIDATED GEMS, INC.'s Chief Development Officer just cashed-in 8,000 options - July 26, 2022

CONSOLIDATED GEMS, INC.'s Acting Chief Business Officer just disposed of 20,000 shares - July 21, 2022

CONSOLIDATED GEMS, INC.'s Acting Chief Business Officer just disposed of 40,000 shares - July 12, 2022

CONSOLIDATED GEMS, INC.'s President and CEO just picked up 1,620 shares - July 5, 2022

CONSOLIDATED GEMS, INC.'s Chief Financial Officer just picked up 1,451 shares - July 5, 2022

CONSOLIDATED GEMS, INC.'s Chief Development Officer just picked up 1,620 shares - July 5, 2022

Major owner of CONSOLIDATED GEMS, INC. just picked up 95,296 shares - June 28, 2022

CONSOLIDATED GEMS: Unaudited Pro Forma Financial Information On June - June 27, 2022

Submission of Matters to a Vote of Security - June 24, 2022

CONSOLIDATED GEMS, INC. director was just granted 16,475 options - June 23, 2022

CONSOLIDATED GEMS, INC. director was just granted 16,475 options - June 23, 2022

Major owner of CONSOLIDATED GEMS, INC. just disposed of 101,903 shares - June 23, 2022

CONSOLIDATED GEMS, INC. director was just granted 16,475 options - June 23, 2022

CONSOLIDATED GEMS, INC. director was just granted 16,475 options - June 23, 2022

CONSOLIDATED GEMS, INC.'s President and CEO just picked up 8,090 shares - June 7, 2022

Major owner of CONSOLIDATED GEMS, INC. just picked up 751,396 shares - June 3, 2022

Major owner of CONSOLIDATED GEMS, INC. just disposed of 418,738 shares - May 16, 2022

Major owner of CONSOLIDATED GEMS, INC. just picked up 1,109,900 shares - May 16, 2022

CONSOLIDATED GEMS: Cullinan Oncology And Taiho Pharmaceutical Announce Strategic - May 12, 2022

Other definitive proxy statements - April 29, 2022

CONSOLIDATED GEMS: 59 Pm Et CULLINAN ONCOLOGY, INC. ONE MAIN STREET SUITE 520 CAMBRIDGE, MA 02142 D83749-P73372 - April 29, 2022

Major owner of CONSOLIDATED GEMS, INC. just picked up 276,000 shares - April 5, 2022

CONSOLIDATED GEMS, INC. director was just granted 7,800 options - March 25, 2022

CONSOLIDATED GEMS, INC. director was just granted 7,800 options - March 25, 2022

CONSOLIDATED GEMS, INC. director was just granted 7,800 options - March 25, 2022

Major owner of CONSOLIDATED GEMS, INC. was just granted 7,800 options - March 25, 2022

CONSOLIDATED GEMS, INC. director was just granted 7,800 options - March 25, 2022

CONSOLIDATED GEMS, INC. Just Filed Its Annual Report: Net Loss per Share B... - March 17, 2022

CONSOLIDATED GEMS: Cullinan Oncology Provides Corporate Update And - March 17, 2022

Securities to be offered to employees in employee benefit plans - March 10, 2022

CONSOLIDATED GEMS, INC.'s President and CEO was just granted 215,000 restricted shares - March 7, 2022

Departure of Directors or Certain - March 3, 2022

CONSOLIDATED GEMS, INC.'s Chief Medical Officer was just granted 215,000 options - March 2, 2022

CONSOLIDATED GEMS, INC. director just declared ownership of no shares of CONSOLIDATED GEMS, INC. - March 2, 2022

CONSOLIDATED GEMS, INC.'s Chief Medical Officer just declared ownership of no shares of CONSOLIDATED GEMS, INC. - March 2, 2022

CONSOLIDATED GEMS, INC. director was just granted 36,880 options - March 2, 2022

CONSOLIDATED GEMS, INC.'s Chief Legal Officer just picked up 22,500 shares - Feb. 15, 2022

CONSOLIDATED GEMS, INC.'s Acting Chief Business Officer just picked up 16,500 shares - Feb. 15, 2022

CONSOLIDATED GEMS, INC.'s See Remarks just picked up 32,500 shares - Feb. 15, 2022

CONSOLIDATED GEMS, INC.'s Chief Financial Officer just picked up 37,500 shares - Feb. 15, 2022

CONSOLIDATED GEMS, INC.'s Chief Development Officer just picked up 28,500 shares - Feb. 15, 2022

CONSOLIDATED GEMS, INC.'s See Remarks just picked up 37,500 shares - Feb. 15, 2022

Mark N. Lampert just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 14, 2022

CHI Advisors LLC just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 11, 2022

James Tananbaum just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 11, 2022

Morana Jovan-Embiricos just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 10, 2022

The Vanguard Group just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Feb. 9, 2022

Major owner of CONSOLIDATED GEMS, INC. just disposed of 1,187,734 shares - Jan. 13, 2022

Major owner of CONSOLIDATED GEMS, INC. just declared owning 5,278,527 shares of CONSOLIDATED GEMS, INC. - Jan. 10, 2022

Departure of Directors or Certain - Dec. 29, 2021

Mark N. Lampert just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Dec. 20, 2021

CONSOLIDATED GEMS: Cullinan Oncology Announces Updated Phase 1/2A Data For CLN-081 - Dec. 16, 2021

CONSOLIDATED GEMS, INC. Just Filed Its Quarterly Report: Net Loss per Share B... - Nov. 9, 2021

CONSOLIDATED GEMS: Cullinan Oncology Provides Corporate Update And - Nov. 9, 2021

Mark N. Lampert just provided an update on share ownership of CONSOLIDATED GEMS, INC. - Nov. 8, 2021

CONSOLIDATED GEMS, INC.'s President and CEO was just granted 2,710,000 options - Oct. 20, 2021

CONSOLIDATED GEMS, INC.'s President and CEO just declared ownership of no shares of CONSOLIDATED GEMS, INC. - Oct. 20, 2021

CONSOLIDATED GEMS, INC.'s See Remarks just cashed-in 4,000 options - Oct. 20, 2021

CONSOLIDATED GEMS, INC.'s Chief Financial Officer just cashed-in 8,000 options - Oct. 18, 2021

CONSOLIDATED GEMS: Cullinan Oncology Appoints Nadim Ahmed As Chief Executive Officer - Oct. 18, 2021

CONSOLIDATED GEMS, INC.'s See Remarks just disposed of 19,574 shares - Oct. 18, 2021

CONSOLIDATED GEMS, INC.'s See Remarks just disposed of 1,079 shares - Oct. 12, 2021

CONSOLIDATED GEMS, INC.'s See Remarks just cashed-in 4,000 options - Sept. 21, 2021

CONSOLIDATED GEMS, INC.'s See Remarks just disposed of 7,468 shares - Sept. 21, 2021

Major owner of CONSOLIDATED GEMS, INC. just disposed of 3,124 shares - Sept. 20, 2021

Major owner of CONSOLIDATED GEMS, INC. just disposed of 3,556 shares - Sept. 20, 2021

Major owner of CONSOLIDATED GEMS, INC. just disposed of 15,401 shares - Sept. 16, 2021

Major owner of CONSOLIDATED GEMS, INC. just disposed of 13,531 shares - Sept. 16, 2021

Major owner of CONSOLIDATED GEMS, INC. just disposed of 26,468 shares - Sept. 13, 2021

Major owner of CONSOLIDATED GEMS, INC. just disposed of 23,253 shares - Sept. 13, 2021

Sorry, no schedule available for this company

Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed - Feb. 13, 2023

Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference - Feb. 2, 2023

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb. 1, 2023

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - Jan. 24, 2023

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan. 3, 2023

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec. 2, 2022

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results - Nov. 14, 2022

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov. 1, 2022

Cullinan Oncology to Participate in Upcoming Investor Conferences - Nov. 1, 2022

Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 - Oct. 25, 2022

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct. 3, 2022

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sept. 1, 2022

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer - Aug. 15, 2022

Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022 - March 8, 2022

Cullinan Oncology to Present at SVB Leerink’s 11th Annual Global Healthcare Conference - Feb. 7, 2022

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment - Jan. 10, 2022

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients - Dec. 16, 2021

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients - Dec. 13, 2021

Cullinan Oncology to Participate in the Evercore ISI 4th Annual HealthconX Conference - Nov. 22, 2021

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Nov. 9, 2021

 


Feedback